PERSPECTA

News from every angle

← Back to headlines

FDA Schedules Meeting to Reassess Peptide Restrictions

The U.S. Food and Drug Administration is moving forward with plans to reassess restrictions on certain popular peptides, including scheduling an Advisory Committee meeting to decide on potentially lifting them. This development has led to a jump in Hims & Hers stock.

15 Apr, 21:39 — 15 Apr, 21:39
PostShare

Sources

Showing 1 of 2 sources
marketwatchMostly Factual134d ago

Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides

Hims & Hers Health’s plan to enter the business of selling peptides is looking a lot more realistic.

By Jaimy Lee

Read full article →

Coverage Timeline

First report: seeking-alpha · 15 Apr, 17:42Full coverage: 2 · 4hWindow: 4h
Left-leaningCenterRight-leaning
seeking-alpha15 Apr, 17:42First to report

FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides

4h later
marketwatch15 Apr, 21:39Latest update

Hims & Hers stock jumps as U.S. moves forward with plan to reassess popular peptides

Related Stories

Cyclospora Outbreak Linked to Iceberg Lettuce Expands to Three Additional States

3h ago

Australian Woman Gives Birth to Twins Fathered by Two Different Men

5h ago

U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates

9h ago

West Nile Virus Outbreaks Spread Across Greece and North Macedonia

10h ago